H. Lundbeck A/S HLUN-A.CO
Nasdaq Copenhagen · Healthcare · Drug Manufacturers - Specialty & Generic
51.60 DKK
+1.2%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for H. Lundbeck
| DKK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 18,246 | 19,912 | 22,004 | 24,630 |
| EBITDA | 4,388 | 5,059 | 5,708 | 6,866 |
| Net income | 1,916 | 2,290 | 3,143 | 3,192 |
| Balance sheet | ||||
| Equity | 20,779 | 22,045 | 25,010 | 24,903 |
| Total debt | 5,579 | 4,151 | 16,693 | 11,654 |
| Cash | 3,421 | 5,010 | 4,664 | 3,433 |
| Net debt | 2,158 | −859 | 12,029 | 8,221 |
| Ratios and per share | ||||
| EBITDA margin | 24.0% | 25.4% | 25.9% | 27.9% |
| Profit margin | 10.5% | 11.5% | 14.3% | 13.0% |
| Return on equity | 9.2% | 10.4% | 12.6% | 12.8% |
| Earnings/share (DKK) | 1.93 | 2.31 | 3.17 | 3.22 |
| Book value/share (DKK) | 20.93 | 22.22 | 25.23 | 25.10 |
| Shares outstanding (M) | 993 | 992 | 991 | 992 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 16.0 |
| P/B | 2.1 |
| EV / EBITDA | 8.7 |
| Net debt / EBITDA | 1.2 |
| Return on equity | 12.8% |
| Profit margin | 13.0% |
| Beta 1Y | 0.64 |
| Revenue growth 1Y | +11.9% |
| Revenue CAGR 3Y | +10.5% |
| Earnings/share CAGR 3Y | +18.6% |
| ROE avg. 3Y | 11.9% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (DKK)
| 2026 | 1.15 |
| 2025 | 0.95 |
| 2024 | 0.70 |
| 2023 | 0.58 |
Not investment advice. Figures may contain errors from the data source.